Financial News · Live Terminal

Page 486 of 532

Tesla's Full Self-Driving System Penetration Seen to Increase to Over 50%, Wedbush Says

Tesla (TSLA) could see penetration of its Full Self-Driving supervised system, or FSD, rise to more than 50%, which would change the financial model of the company moving forward, Wedbush said in a Tuesday note ahead of the company's Q1 earnings on Wednesday.The company received regulatory approval for the FSD system in the Netherlands, its first approval in Europe, Wedbush analysts said. The development lays the groundwork to obtain approval for the rest of Europe, with Germany, France and Italy anticipated to follow suit over the coming months, the analysts said.Wall Street's estimate of about $22.4 billion in Q1 revenue, with Tesla's automotive segment at around $16 billion, is not surprising given the weak demand in Europe and the US, the analysts said. Tesla's Q1 EPS is projected at $0.37, reflecting the investments it has made across the company to focus more on artificial intelligence, according to the note.At its Q1 earnings conference call on Wednesday after-market, the analysts expect Tesla to elaborate more on its AI initiatives after around $20 billion in AI capital expenditures on Cybercab, semi production, and a new mega factory.Wedbush maintained the company's stock rating at outperform and price target at $600.Price: $389.07, Change: $-3.43, Percent Change: -0.87%

$TSLA

Wire110d ago

Update: Halliburton Shares Rise After Q1 Beat

(Updates with the latest stock price movement in the headline and the first paragraph.)Halliburton (HAL) shares rose more than 4% on Tuesday after the company reported higher-than-expected Q1 adjusted earnings and revenue.The company reported Q1 adjusted net income Tuesday of $0.55 per diluted share, down from $0.60 a year earlier.Analysts polled by FactSet expected $0.50.Revenue for the quarter ended March 31 was $5.40 billion, down from $5.42 billion a year earlier.Analysts surveyed by FactSet expected $5.31 billion.Price: $38.19, Change: $+1.51, Percent Change: +4.12%

$HAL

Wire110d ago

Market Chatter: Deutsche Telekom to Consider Full Combination With T-Mobile US

T-Mobile's (TMUS) largest shareholder, Deutsche Telekom, is mulling a full combination with the US-based carrier in what would be the largest-ever public M&A deal, Bloomberg reported Tuesday, citing people with knowledge of the matter.The German carrier, which owns a 53% stake in T-Mobile, has been considering creating a new holding company that would make a stock bid for shares of both companies, the report said.The companies didn't immediately reply to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $201.25, Change: $+2.88, Percent Change: +1.45%

$TMUS

Wire110d ago

Passage Bio Faces Tougher FDA Road After Trial Shift, Wedbush Says

Passage Bio (PASG) faces a tougher path after US regulators told the company it will need to run a randomized study to support approval of its experimental treatment PBFT02, a move that adds time, cost, and uncertainty, Wedbush Securities said Tuesday in a report.A randomized trial of PBFT02 for frontotemporal dementia would be expensive and slow, though the condition has no approved treatments, the report said.Biomarker results from the ongoing study still look promising, and new MRI data adds support that the therapy could help patients, Wedbush said.Wedbush downgraded Passage Bio's stock to neutral from outperform and cut its price target to $8 from $32 after removing PBFT02 from its valuation, saying the treatment may still have potential but the regulatory hurdles are now too high to support a more positive view.Passage Bio ended 2025 with $46.3 million in cash, and Wedbush's new price target reflects projected cash per share by the end of 2026 after double-digit operating-expense cuts in the coming quarters, according to the report.Price: $6.01, Change: $-0.24, Percent Change: -3.84%

$PASG

Wire110d ago

Update: Market Chatter: Coinbase Global, Gemini Titan Sued by New York for Prediction Markets Allegedly Being Illegal Gambling

(Updates with statement from Coinbase in the fourth paragraph.)Coinbase Global (COIN) and Gemini Titan have been sued by New York Attorney General Letitia James for allegedly violating the state laws against illegal gambling with their prediction markets, Reuters reported Tuesday, citing complaints filed in a state court in Manhattan.James said that the two companies neglected to obtain licenses from the New York State Gaming Commission for the markets, which fit under the state's definition of gambling, according to the report. The attorney general added the two companies also allowed 18- to 20-year-olds use their platforms, going against the state's minimum age of 21 for mobile sports betting, the report said.James aims to recoup illegal profits, impose civil penalties triple of the amount, and provide restitution to customers, as well as to ban Coinbase and Gemini from allowing people under 21 to wager, the report said.Coinbase toldthat prediction markets are federally regulated national exchanges registered with the Commodity Futures Trading Commission. "Coinbase will continue to fight for the federal oversight of these markets that Congress intended," Chief Legal Officer Paul Grewal said.Gemini Titan did not immediately reply to a request for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $198.34, Change: $-13.29, Percent Change: -6.28%

$COIN

Wire110d ago

KeyBanc Cuts McDonald's Price Target to $345 From $354

McDonald's (MCD) has an average rating of overweight and mean price target of $346.68, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $302.07, Change: $-4.87, Percent Change: -1.59%

$MCD

Wire110d ago

Evercore ISI Adjusts Danaher Price Target to $225 From $210, Maintains Outperform Rating

Quest Diagnostics (DGX) has an average rating of overweight and mean price target of $219, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $203.42, Change: $+7.11, Percent Change: +3.62%

$DGX

Wire110d ago

Sprouts Farmers Market to Likely Deliver Relatively In-Line Q1, RBC Says

Sprouts Farmers Market (SFM) is expected to deliver "in-line" Q1 results and reaffirm 2026 forecast, with modestly improving comparable sale trends, RBC Capital Markets said in a report Tuesday.RBC said it raised its Q1 comparable sales estimate to a 1.5% decline from a prior 2% drop, now slightly ahead of consensus expectations, citing improved "transaction data" since mid-February. Adjusted earnings per share are projected to remain at $1.69, roughly in line with Wall Street estimates, as continued investments in pricing and loyalty programs weigh on margins, the firm said.Sprouts Farmers Market is scheduled to release its Q1 financial results on April 29.The brokerage said it expects the company's management to reaffirm its 2026 guidance following the release, noting that quarter-to-date trends have remained "steady" and should support "confidence" in maintaining 2-year stack for Q2 assumptions. Comparable sales for Q2 are forecast in a range of down 2% to flat, broadly aligning with consensus, according to the report.RBC said "primary focus" is expected to be on April comparable sales performance as a key indicator of whether comps can begin to "accelerate" after cycling through tougher year-ago comparisons.RBC has an outperform rating on Sprouts Farmers Market, with an unchanged price target of $114.Price: $74.65, Change: $+0.30, Percent Change: +0.40%

$SFM

Wire110d ago

Arcus Biosciences Has Favorable Setup After Merck Belzutifan Failure, Wedbush Says

Arcus Biosciences (RCUS) shares have a favorable setup following Merck's (MRK) belzutifan phase 3 failure in Litespark-012, with Wedbush Securities saying the readout does not represent negative readthrough for Arcus' casdatifan and highlights a differentiated profile in clear cell renal cell carcinoma, or RCC.The brokerage said in a Tuesday note that the Merck data do not impact Arcus' TKI-free frontline strategy and that casdatifan remains supported by a more optimal development approach and stronger comparative efficacy versus belzutifan.Wedbush also said recent weakness following the discontinuation of Arcus' domvanalimab program has created an attractive entry point ahead of upcoming clinical data readouts, reinforcing a favorable setup for the stock.The firm reiterated its outperform rating on the stock and price target of $41 per share.Price: $23.31, Change: $+0.57, Percent Change: +2.51%

$MRK$RCUS

Wire110d ago

JPMorgan Cuts Price Target on Danaher to $245 From $275, Maintains Overweight Rating

Danaher (DHR) has an average rating of Buy and mean price target of $254.19, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $191.43, Change: $-4.07, Percent Change: -2.08%

$DHR

Wire110d ago

Deutsche Telekom Said to Consider Full Combination With T-Mobile US, Bloomberg Reports

$TMUS

Wire110d ago

Jefferies Adjusts Price Target on Danaher to $245 From $240, Maintains Buy Rating

$DHR

Wire110d ago

Donnelley Financial Solutions Board Authorizes $150 Million Share Buyback Program

Donnelley Financial Solutions (DFIN) said in a regulatory filing Tuesday that on April 16, the company's board approved a new share buyback program of up to $150 million of common stock.The company said the program began on April 17, and will be effective through Dec. 31, 2027, adding that it replaces the prior $150 million program, which had about $15 million left unused.The company said it may repurchase shares on the open market or through private transactions, and the timing and amount will depend on market conditions and other factors.The company added it may also use a Rule 10b5-1 plan to allow repurchases during periods when it might otherwise be restricted from trading. The program can be suspended or discontinued at any time.Shares of Donnelley Financial Solutions were up 1.5% in the session.Price: $53.33, Change: $+0.80, Percent Change: +1.52%

$DFIN

Wire110d ago

Perpetuals.com's BayesShield AI Platform to Be Deployed Across German UDS Research Centers

Perpetuals.com (PDC) has entered into a licensing agreement with the German University of Digital Science to integrate its BayesShield AI predictive intelligence platform across the university's research centers and digital learning infrastructure, the university said Tuesday.Under the agreement, German UDS said it will deploy BayesShield AI within its Research Center for Artificial Intelligence, Research Center for Cybersecurity, and Research Center for Digital Transformations.Students and faculty will use BayesShield's AI models to analyze real-world trading patterns, conduct research on retail investor behavior, and develop risk management frameworks, the university said.The university also said its six research centers will help advance BayesShield's machine learning models and publish research output in peer-reviewed journals.Shares of Perpetuals.com fell more than 12% in Tuesday trading.Price: $6.92, Change: $-0.96, Percent Change: -12.18%

$PDC

Wire110d ago

Jefferies Raises Quest Diagnostics Price Target to $225 From $220

$DGX

Wire110d ago

Truist Securities Cuts Tractor Supply Price Target to $44 From $55, Hold Rating Kept

Tractor Supply (TSCO) has an average rating of overweight and mean price target of $56.19, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $39.92, Change: $-4.90, Percent Change: -10.92%

$TSCO

Wire110d ago

Apple's Incoming CEO Faces Crucial AI Test, Wedbush Says

Apple's (AAPL) incoming CEO, John Ternus, needs to get the company's AI strategy right and sharpen its approach to turning that technology into new revenue streams, Wedbush Securities said Tuesday in a report.Apple's software and services growth depends on its "unrivaled" installed base, and innovation around foldable devices, an AI-enabled iPhone, and more affordable Apple Glasses will be central to the company's next chapter, the report said.Ternus is expected to bring in more outside innovation, and a shift away from Apple's historically cautious stance on mergers and acquisitions will be important, Wedbush said."Apple has more cash, consumers, and brand recognition than any company in theworld," the report said. "Now is the time to flex the muscles and go on the offensive instead of the defensive."Tim Cook is stepping down as CEO and will become executive chairman, effective Sept. 1. Ternus currently is senior vice president of hardware engineering.Wedbush maintained its outperform rating on Apple stock with a $350 price target.Price: $266.22, Change: $-6.83, Percent Change: -2.50%

$AAPL

Wire110d ago

Erasca Says Phase 1 Data Readout for ERAS-0015 Expected in May

Erasca (ERAS) said in a filing Tuesday that it has narrowed the timeline for the data readout of its phase 1 trials evaluating its pan-RAS molecular glue ERAS-0015 to not later than mid-May, compared with prior guidance of H1.The company is evaluating ERAS-0015 in a phase 1 trial in patients with RAS-mutant solid tumors, while its licensor Guangzhou Joyo Pharmatech is evaluating ERAS-0015 in patients with advanced solid tumors harboring specific RAS mutations in China, according to a filing with the US Securities and Exchange Commission.Shares of Erasca were up 3.9% in Tuesday trading.Price: $22.55, Change: $+0.84, Percent Change: +3.87%

$ERAS

Wire110d ago

Kemper Completes Sale of Newins Distribution Operation to Confie

Kemper (KMPR) said Tuesday that it has completed its sale of Newins property and casualty distribution operations to Confie.The transaction includes the sale of Newins Insurance Agency, which operates under the Illinois Vehicle, A-Abana, and Access Auto Insurance brands in a limited number of states, the company said.Shares of the company were down 1.7% in Tuesday trading.Price: $33.11, Change: $-0.44, Percent Change: -1.31%

$KMPR

Wire110d ago

Intel Poised for 'Slight Beat' Amid Solid Server CPU Demand, RBC Says

Intel (INTC) is expected to report a "slight beat" in its fiscal first-quarter results amid robust server central processing unit demand, RBC Capital Markets said in a note e-mailed Tuesday.On Thursday, the chipmaker is likely to post adjusted per-share earnings and revenue above RBC's projections for breakeven and $12.20 billion, respectively, for the March quarter, according to the brokerage. The current consensus on FactSet is for non-GAAP EPS of $0.02 and sales of $12.42 billion."We expect a slight beat/raise driven by strong server CPU demand," RBC analyst Srini Pajjuri said. "(Personal computer) market also appears to be holding up for now."First-quarter revenue in the company's data center and artificial intelligence segment is pegged at $4.3 billion, representing a 3% annual gain, with room for potential upside, according to RBC."While demand remains strong, management expected internal wafer supply constraints to be most acute in (the first quarter) which could limit near-term upside," Pajjuri wrote. "Recent media reports point to Intel raising prices which should help."For the current quarter, RBC expects Intel to issue an outlook above Wall Street's estimates of $13.1 billion in revenue and adjusted EPS of $0.09, driven by server CPU demand and improving wafer supply.The data center and AI business is projected to see sequential growth of 10% in the second quarter, with RBC seeing potential upside amid improving supply and healthy pricing. The brokerage expects server demand to continue to benefit from agentic AI and sees industry supply remaining "tight" through 2026, it said in the note.RBC maintained its sector perform rating on Intel's stock with a $48 price target.The company's shares were up 0.3% in Tuesday afternoon trade, bringing its year-to-gains to nearly 79%.Last year, the US government agreed to invest $8.9 billion in Intel's common stock as part of a deal to secure a stake in the company. Separately, Nvidia (NVDA) agreed to inject $5 billion in Intel under a collaboration that aims to develop new data center and PC chips.Price: $66.04, Change: $+0.34, Percent Change: +0.52%

$INTC$NVDA

Showing 9701-9720 of 10633

Wire110d ago

Intel Poised for 'Slight Beat' Amid Solid Server CPU Demand, RBC Says

$INTC$NVDA